Attenuation of the lordosis-inhibiting effects of 8-OH-DPAT by TFMPP and quipazine
Autor: | Lynda Uphouse, Astra Jackson, Marjay Caldarola-Pastuszka, A Trevino, T Price, Amy Wolf |
---|---|
Rok vydání: | 1998 |
Předmět: |
Agonist
endocrine system medicine.medical_specialty Lordosis medicine.drug_class Posture Piperazines Sexual Behavior Animal chemistry.chemical_compound Estrus Internal medicine medicine Animals Molecular Biology 8-Hydroxy-2-(di-n-propylamino)tetralin 8-OH-DPAT musculoskeletal neural and ocular physiology General Neuroscience Quipazine medicine.disease Lordosis behavior Rats Inbred F344 Rats Serotonin Receptor Agonists Endocrinology Ventromedial nucleus of the hypothalamus nervous system chemistry Female Neurology (clinical) Serotonin Developmental Biology medicine.drug |
Zdroj: | Brain Research. 804:206-211 |
ISSN: | 0006-8993 |
Popis: | Regularly cycling, proestrous female rats received infusions of 200 ng of the serotonin (5-HT) 1A receptor agonist, (+/-) 8-hydroxy 2-(di-n-propylamino) tetralin-HBr (8-OH-DPAT), or 200 ng 8-OH-DPAT and 1000 or 2000 ng of N-(3-trifluoro-methylphenyl) piperazine hydrochloride (TFMPP) or 2-(1-piperazinyl) quinoline dimaleate (quipazine). Infusions were made bilaterally into the ventromedial nucleus of the hypothalamus (VMN). Animals receiving 200 ng 8-OH-DPAT exhibited a decline in lordosis behavior following infusion. Rats receiving 8-OH-DPAT and 1000 or 2000 ng quipazine or TFMPP were protected from the lordosis-inhibiting effects of 8-OH-DPAT, alone. Although both quipazine and TFMPP act on multiple 5-HT receptors, they overlap in their agonist action at 5-HT2 receptors. Consequently, these results provide further evidence supporting the contention that within the VMN, both 5-HT1A and 5-HT2 receptor subtypes contribute to the modulation of lordosis behavior in the female rat. The data are discussed in terms of the relative potency of 5-HT at 5-HT receptors mediating inhibition and facilitation of lordosis behavior. |
Databáze: | OpenAIRE |
Externí odkaz: |